Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023

MARLBOROUGH, MA, USA I April 17, 2023 I Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 (mPH-762) exerts systemic anti-tumor efficacy (“abscopal effect”).

In the study, intratumoral administration of mPH-762 stimulated a local anti-tumor immune response and generated systemic tumor-reactive memory T cells, suggesting that the abscopal effects of PH-762 are mediated by the immune system.  

“These preclinical study results support intratumoral use of PH-762 in the clinical setting, with deeper understanding of the mechanism of abscopal efficacy,” said Dr. Mary Spellman, Phio’s Acting Chief Medical Officer. “In addition, immune-related adverse events noted with systemic PD-1 inhibition may be mitigated by intratumoral administration.”

PH-762 is under clinical development in a phase 1b trial for neoadjuvant treatment of advanced resectable melanoma.

Presentation Details:  
Poster Title: Intratumoral PH-762, a self-delivering RNAi therapeutic (INTASYL™) targeting mouse PD-1, generates systemic tumor-specific memory CD8 T cells, providing a mechanism for abscopal efficacy toward untreated tumors in a murine hepatocarcinoma model.
Session Date and Time: Monday, April 17, 2023 from 9:00 AM – 12:30 PM EST

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

For additional information, visit the Company’s website, www.phiopharma.com.   

SOURCE: Phio Pharmaceuticals